OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Prat on HER2-Enriched Subtype as Strong Predictor of HER2-Targeted Treatment

December 15th 2016

Aleix Prat, MD, PhD, head of the Department of Medical Oncology, the August Pi i Sunyer Biomedical Research Institute, discusses the results of the open-label PAMELA trial, in which the HER2-enriched subtype predicted pathologic complete response to targeted treatment in patients with HER2-positive, hormone receptor-positive breast cancer.

Dr. Mutti on Predicting Response to Immunotherapy for Mesothelioma

December 15th 2016

Luciano Mutti, MD, professor in Cancer Research, University of Salford Manchester, discusses predicting clinical response to immunotherapy agents for patients with mesothelioma.

Dr. Younes on 2016 ASH Highlights in Mantle Cell Lymphoma

December 15th 2016

Anas Younes, MD, chief of the Lymphoma Service at Memorial Sloan Kettering Cancer, discusses highlights from the 2016 ASH Annual Meeting focused on the area of mantle cell lymphoma (MCL).

Dr. Koyfman on Risk Categories in the Reirradiation Setting of Recurrent Head and Neck Cancer

December 15th 2016

Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses risk categories that stratified patients in a study evaluating intensity-modulated radiation therapy and stereotactic body radiation therapy to determine outcomes in the reirradiation setting for recurrent head and neck cancer.

Dr. Venook on Immunotherapy Potential in Colorectal Cancer

December 15th 2016

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the potential that immunotherapy may have in the treatment of patients with colorectal cancer.

Dr. Rimawi on Neoadjuvant Estrogen Deprivation Therapy in HER2+ Breast Cancer

December 15th 2016

Mothaffar F. Rimawi, MD, associate professor and medical director at the Lester and Sue Smith Breast Center at the Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, discusses the findings of the NSABP B-52 trial, which explored the addition of neoadjuvant estrogen deprivation therapy to docetaxel and carboplatin plus the HER2 inhibitors trastuzumab (Herceptin) and pertuzumab (Perjeta) as treatment for patients with HER2-positive breast cancer.

Dr. Zamarin on Novel Immunotherapy Approaches in Gynecologic Cancers

December 14th 2016

Dmitriy Zamarin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses some of the novel approaches with immunotherapy that he would like to explore in the future treatment of patients with gynecologic cancers.

Dr. Klopp on a Comparison of Standard Radiation to IMRT in Gynecologic Malignancies

December 14th 2016

Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, discusses the results of a study that compared the respective toxicities and quality of life outcomes associated with standard radiation and pelvic intensity-modulated radiation therapy for patients with various gynecologic malignancies.

Dr. Dieras on Combo of Veliparib and Chemotherapy in BRCA1/2-Mutant Breast Cancer

December 13th 2016

Véronique Diéras, MD, Department of Clinical Research, Institut Curie Paris & Saint Cloud, discusses results of a phase II trial exploring the combination of the PARP inhibitor veliparib with chemotherapy in patients with BRCA1/2-mutant breast cancer.

Brock Schroeder Discusses BCI Findings in ER+ Breast Cancer

December 13th 2016

Brock Schroeder, PhD, senior director, Medical and Scientific Affairs at bioTheranostics, discusses findings regarding the Breast Cancer Index in predicting patients with estrogen receptor (ER)-positive breast cancer at high risk of recurrence.

Dr. Alvarez on Updated Findings With Eribulin in Patients With HER2- Breast Cancer

December 13th 2016

Ricardo H. Alvarez, MD, MSc, director of Cancer Research, breast medical oncologist, Southeastern Regional Medical Center, Cancer Treatment Centers of America, discusses updated findings regarding the mechanism of action with eribulin mesylate (Halaven) and how it impacts patients with HER2-negative breast cancer.

Dr. Pollack on the Role of Radiomics in Sarcoma

December 13th 2016

Seth M. Pollack, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the role of radiomics in the treatment landscape of sarcoma.

Dr. Birrer on the Need for Novel Treatment Options in Cervical Cancer

December 13th 2016

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses some of the novel treatment options that could be explored in the future treatment of patients with cervical cancer.

Dr. Nangia on the SCALP Trial for Early-Stage Breast Cancer

December 12th 2016

Julie R. Nangia, MD, assistant professor, Breast Center-Clinic, faculty senator, Baylor College of Medicine, discusses the results of the Scalp Cooling Alopecia Prevention trial (SCALP) for patients with early-stage breast cancer.

Dr. Bajorin on Chemotherapy Approaches in Bladder Cancer

December 6th 2016

Dean F. Bajorin, MD, professor of Medicine, Memorial Sloan Kettering Cancer Center, discusses the standard chemotherapy approaches for patients with metastatic and muscle-invasive bladder cancer.

Dr. Lee on Sequencing Therapies for Patients With RCC

December 6th 2016

Chung-Han (Joe) Lee, MD, medical oncologist Memorial Sloan Kettering Cancer Center, discusses sequencing therapies for patients with renal cell carcinoma (RCC).

Dr. Kantarjian on Future Role of Chemotherapy in Patients With ALL

December 3rd 2016

Hagop M. Kantarjian, MD, professor, department of Leukemia, division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the evolving and future role of chemotherapy in the treatment paradigm of acute lymphoblastic leukemia (ALL).

Dr. Mesa on Upcoming Updates to NCCN Guideline for MPNs

December 3rd 2016

Ruben A. Mesa, MD, chair of Hematology, Mayo Clinic, discusses updates that are expected in 2017 to the NCCN Guideline for Myeloproliferative Neoplasms (MPNs).

Dr. Michael J. Morris on Radium-223 Combination Options for mCRPC

December 2nd 2016

Michael J. Morris, MD, an associate professor of Medicine at Memorial Sloan Kettering Cancer, discusses the benefits of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Berk on the Role of Hospitals Versus Independents

December 2nd 2016

As insurers and the federal government look for ways to reduce costs in oncology, the division of care between large, academic institutions and smaller providers is undergoing a process of change, says Seth Berk, MD, chair of the Financial Audit Committee for Regional Cancer Care Associates (RCCA) and a Mount Holly, New Jersey, specialist in internal medicine, hematology and oncology.